Pills leaning against coinsRemdesivir, one of the few coronavirus treatments, costs private health plans more than $3,000 per treatment course, though the World Health Organization has said there's no evidence the drug reduces patient deaths.

(Bloomberg) –The U.S. government should set prices for coronavirus vaccines and therapies to prevent gouging, a coalition of companies and other employers said.

Medicare, the health program serving older Americans, should determine fair prices for COVID-19 drugs and inoculations that would also be paid by companies, organizations and individuals, Employers' Prescription for Affordable Drugs said in a statement. The group cited Gilead Sciences Inc.'s remdesivir antiviral as an example of an overpriced therapy.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.